BridgeBio Pharma, Inc. (BBIO)
67.25
+0.34
(+0.51%)
USD |
NASDAQ |
Oct 02, 16:00
67.23
-0.02
(-0.03%)
After-Hours: 20:00
BridgeBio Pharma Enterprise Value : 15.82B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 15.82B |
| October 01, 2026 | 15.76B |
| September 30, 2026 | 15.54B |
| September 29, 2026 | 15.57B |
| September 28, 2026 | 15.70B |
| September 25, 2026 | 15.50B |
| September 24, 2026 | 15.63B |
| September 23, 2026 | 15.52B |
| September 22, 2026 | 16.21B |
| September 21, 2026 | 15.69B |
| September 18, 2026 | 15.70B |
| September 17, 2026 | 15.84B |
| September 16, 2026 | 16.03B |
| September 15, 2026 | 16.05B |
| September 14, 2026 | 16.83B |
| September 11, 2026 | 16.84B |
| September 10, 2026 | 16.85B |
| September 09, 2026 | 17.55B |
| September 08, 2026 | 17.29B |
| September 04, 2026 | 17.31B |
| September 03, 2026 | 17.42B |
| September 02, 2026 | 17.63B |
| September 01, 2026 | 17.64B |
| August 31, 2026 | 17.65B |
| August 28, 2026 | 17.65B |
| Date | Value |
|---|---|
| August 27, 2026 | 18.06B |
| August 26, 2026 | 18.19B |
| August 25, 2026 | 18.39B |
| August 24, 2026 | 18.52B |
| August 21, 2026 | 18.61B |
| August 20, 2026 | 18.89B |
| August 19, 2026 | 19.09B |
| August 18, 2026 | 18.90B |
| August 17, 2026 | 18.29B |
| August 14, 2026 | 18.29B |
| August 13, 2026 | 18.55B |
| August 12, 2026 | 19.06B |
| August 11, 2026 | 19.04B |
| August 10, 2026 | 19.23B |
| August 07, 2026 | 19.19B |
| August 06, 2026 | 18.86B |
| August 05, 2026 | 18.70B |
| August 04, 2026 | 18.72B |
| August 03, 2026 | 18.31B |
| July 31, 2026 | 18.33B |
| July 30, 2026 | 18.73B |
| July 29, 2026 | 19.01B |
| July 28, 2026 | 19.40B |
| July 27, 2026 | 19.12B |
| July 24, 2026 | 19.10B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Ionis Pharmaceuticals, Inc. | 7.346B |
| Pfizer Inc. | 210.23B |
| BioMarin Pharmaceutical, Inc. | 14.41B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -155.89M |
| Revenue (Quarterly) | 243.68M |
| Total Expenses (Quarterly) | 395.89M |
| EPS Diluted (Quarterly) | -0.7775 |
| Gross Profit Margin (Quarterly) | 93.68% |
| Profit Margin (Quarterly) | -63.97% |
| Earnings Yield | -5.31% |
| Normalized Earnings Yield | -5.306 |